BridgeBio Pharma (BBIO) Interest Coverage Ratio (2018 - 2026)
BridgeBio Pharma recorded quarterly Interest Coverage Ratio of 8.19 in Q1 2026, up 31.74% quarter-over-quarter from 11.99 in Q4 2025, and down 42.14% year-over-year from 14.15 in Q1 2025.
BridgeBio Pharma's Interest Coverage Ratio history runs 9 years deep, the most recent figure standing at 8.19 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 42.14% year-over-year to 8.19; the TTM figure through Mar 2026 stood at 7.1 (up 12.86% YoY), while the FY2025 annual figure was 9.86, down 51.25% from the prior year.
- Interest Coverage Ratio came in at 8.19 for Q1 2026 at BridgeBio Pharma, up from 11.99 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.01 in Q1 2024 to a low of 12.37 in Q3 2025.
- A 5-year average of 7.28 and a median of 7.65 in 2024 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio surged 100.23% in 2024 and plunged 39512.98% in 2025, its largest moves.
- BridgeBio Pharma's Interest Coverage Ratio stood at 6.46 in 2022, then tumbled by 35.4% to 8.75 in 2023, then retreated by 19.98% to 10.5 in 2024, then fell by 14.21% to 11.99 in 2025, then surged by 31.74% to 8.19 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 8.19, 11.99, and 12.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 3.88 |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -8.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.19 |
| Dec 31, 2025 | -11.99 |
| Sep 30, 2025 | -12.37 |
| Jun 30, 2025 | -3.57 |
| Mar 31, 2025 | -5.76 |
| Dec 31, 2024 | -10.50 |
| Sep 30, 2024 | -8.31 |
| Jun 30, 2024 | -7.65 |
| Mar 31, 2024 | 0.01 |
| Dec 31, 2023 | -8.75 |
| Sep 30, 2023 | -7.77 |
| Jun 30, 2023 | -7.09 |
| Mar 31, 2023 | -6.27 |
| Dec 31, 2022 | -6.46 |
| Sep 30, 2022 | -6.51 |
| Jun 30, 2022 | -3.95 |
| Mar 31, 2022 | -8.54 |
| Dec 31, 2021 | -10.94 |
| Sep 30, 2021 | -13.51 |
| Jun 30, 2021 | -8.67 |
| Mar 31, 2021 | -17.20 |
| Dec 31, 2020 | -11.63 |
| Sep 30, 2020 | -10.97 |
| Jun 30, 2020 | -11.58 |
| Mar 31, 2020 | -25.56 |
| Dec 31, 2019 | -25.87 |
| Sep 30, 2019 | -25.81 |
| Jun 30, 2019 | -35.71 |
| Mar 31, 2019 | -38.15 |
| Dec 31, 2018 | -55.63 |
| Sep 30, 2018 | -35.86 |
| Jun 30, 2018 | -169.67 |